Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults
- Resource Type
- Article
- Source
- In
Clinical Gastroenterology and Hepatology June 2022 20(6):1299-1305 - Subject
- Language
- ISSN
- 1542-3565